Brachytherapy Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Alerts
• Clinical Trials
• Forums

Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC
Condition:   Hepatocellular Carcinoma Non-resectable Interventions:   Procedure: Lenvatinib Plus I-125 Seed Brachytherapy;   Drug: Lenvatinib Sponsor:   Second Affiliated Hospital of Guangzhou Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 8, 2022 Category: Research Source Type: clinical trials